Intrinsiqq
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. Insider Trading

BCAX

Compare
Last 12 months

Insiders sold $9.68M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market
−$9.68M
0 buys · 32 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
0 / 4
executives and directors
Last open-market buy
None
in the last two years

Get an email when BCAX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Sep 810b5-1 plan
    Ryan Cohlhepp
    President, COO & Interim CEO · sold 17,500 at avg $22.90
    401K
    8.8% of stake
  • Aug 1010b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 12,500 at $27.97
    350K
    8.8% of stake
  • Aug 1010b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 10,000 at $27.98
    280K
    2.7% of stake
  • Aug 1010b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 18,750 at $27.98
    525K
    9.4% of stake
  • Jul 1010b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 10,000 at avg $28.42
    284K
    2.7% of stake
  • Jul 8 – 910b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 28,750 at avg $28.98
    833K
    14% of stake
  • Jul 810b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 28,000 at avg $28.84
    808K
    18% of stake
  • May 2110b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 9,200 at $20.42
    188K
    6.0% of stake
  • May 1810b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 15,000 at avg $20.04
    301K
    4.0% of stake
  • May 1510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $20.29
    254K
    6.1% of stake
  • Apr 2710b5-1 plan
    David Raben
    Chief Medical Officer · sold 5,500 at $22.88
    126K
    9.0% of stake
  • Apr 2110b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 9,200 at $23.00
    212K
    6.0% of stake
  • Apr 2010b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 15,000 at $23.61
    354K
    4.0% of stake
  • Apr 1510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $23.01
    288K
    6.0% of stake
  • Mar 2510b5-1 plan
    David Raben
    Chief Medical Officer · sold 5,500 at $18.95
    104K
    9.0% of stake
  • Mar 2310b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 9,200 at $18.52
    170K
    6.0% of stake
  • Mar 18 – 2010b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 15,000 at avg $18.82
    282K
    4.2% of stake
  • Mar 1610b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $19.66
    246K
    5.9% of stake
  • Mar 910b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 36,766 at $19.17
    705K
    9.8% of stake
  • Mar 4 – 610b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 8,234 at avg $18.74
    154K
    2.4% of stake
  • Mar 3 – 410b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 16,518 at avg $18.23
    301K
    10% of stake
  • Mar 3 – 410b5-1 plan
    David Raben
    Chief Medical Officer · sold 16,500 at avg $18.52
    306K
    23% of stake
  • Mar 310b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 17,392 at avg $18.16
    316K
    7.8% of stake
  • Feb 26
    RA Capital Management, L.p.
    Large holder · bought 300,000 at $16.00
    $4.8M
    7.0% of stake
  • Feb 2510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 3,631 at avg $18.04
    66K
    1.7% of stake
  • Jan 2210b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 3,828 at $18.10
    69K
    1.8% of stake
  • Jan 2210b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 1,882 at $18.15
    34K
    1.3% of stake
  • Jan 1510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 149 at $18.02
    3K
    <0.1% of stake
  • Dec 22, 202510b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 9,200 at $18.31
    168K
    6.0% of stake
  • Dec 15, 202510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $18.68
    234K
    6.2% of stake
  • Nov 24, 2025 – Nov 25, 202510b5-1 plan
    David Raben
    Chief Medical Officer · sold 11,000 at avg $18.65
    205K
    24% of stake
  • Nov 24, 202510b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 41,163 at $18.86
    776K
    12% of stake
  • Nov 21, 2025 – Nov 24, 202510b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 18,400 at avg $18.54
    341K
    11% of stake
  • Nov 21, 202510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $18.05
    226K
    6.1% of stake
  • Oct 16, 202510b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 24,103 at $18.83
    454K
    7.2% of stake
  • Oct 15, 202510b5-1 plan
    Ryan Cohlhepp
    President and COO · sold 12,500 at avg $18.16
    227K
    5.9% of stake
  • Oct 13, 2025 – Oct 15, 202510b5-1 plan
    Claire Mazumdar
    Chief Executive Officer · sold 24,734 at avg $18.88
    467K
    7.4% of stake
  • Oct 9, 202510b5-1 plan
    David Raben
    Chief Medical Officer · sold 22,000 at $18.45
    406K
    38% of stake
  • Oct 9, 202510b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 6,415 at $18.23
    117K
    4.2% of stake
  • Oct 6, 2025 – Oct 8, 202510b5-1 plan
    Ivan Hyep
    Chief Financial Officer · sold 30,385 at avg $18.21
    553K
    17% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BCAX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BCAX

CompareIntrinsic value
JANXJanux Therapeutics Inc.
$10.08-2.04%40
IRWDIronwood Pharmaceuticals Inc.
$4.70-0.21%63
RIGLRigel Pharmaceuticals, Inc.
$40.09-2.67%86
CAPRCapricor Therapeutics Inc.
$7.59+0.80%10
ABVCABVC BioPharma Inc.
$0.87-1.56%0
GOSSGossamer Bio Inc.
$10.72-4.54%10
CRBPCorbus Pharmaceuticals Holdings, Inc.
$2.06-15.40%10
IBIOiBio, Inc.
$0.80+0.01%10

Held by ETFs

BCAX is in 30 US ETFs. The largest of them, with BCAX's weight in each:

Spot a number that looks wrong? Check it in BCAX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing BCAX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.